All In Biotech

NDA 021636 · Salix

Zegerid

Omeprazole, Sodium Bicarbonate · Oral · Proton Pump Inhibitor

Discontinued

Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jun 15, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

988

158 Phase 3, 48 recruiting

FAERS reports

2,739

1,742 serious, 167 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 19, 2023.

ZEGERID for oral suspension and ZEGERID capsules are indicated in adults for the : • short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. • short-term treatment (4 to 8 weeks) of active benign gastric ulcer. • treatment of heartburn and other symptoms associated with GERD for up to 4 weeks. • short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD which has been diagnosed by endoscopy in adults. o The efficacy of ZEGERID used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of ZEGERID may be considered. • maintenance of healing of EE due to acid-mediated GERD. Controlled studies do not extend beyond 12 months. ZEGERID for oral suspension is indicated in adults for the : • reduction of risk of upper GI bleeding in critically ill adult patients. ZEGERID is a proton pump inhibitor (PPI). ZEGERID for oral suspension and ZEGERID capsules are indicated in adults for: • Treatment of active duodenal ulcer ( 1 ) • Treatment of active benign gastric ulcer ( 1 ) • Treatment of erosive esophagitis (EE) due to acid-mediated gastroesophageal reflux disease (GERD) ( 1 ) • Maintenance of healing of EE ( 1 ) ZEGERID for oral suspension is indicated in adults for: • Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients ( 1 )

Mechanism: Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

Therapeutic areas: Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ZEGERID · OMEPRAZOLE 20MG/PACKET; SODIUM BICARBONATE 1.68GM/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · FOR SUSPENSION, ORAL · Discontinued · TE AB
  • ZEGERID · OMEPRAZOLE 40MG/PACKET; SODIUM BICARBONATE 1.68GM/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · FOR SUSPENSION, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Omeprazole" as an intervention, any sponsor and status, largest first.

All 988 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease788
  • acute kidney injury456
  • renal failure431
  • end stage renal disease212
  • drug ineffective200
  • renal injury195
  • nausea167
  • gastrooesophageal reflux disease156
  • pain135
  • headache131
  • fatigue126
  • diarrhoea109

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20057
200614
200726
200862
200986
2010119
2011145
2012142
2013102
201497
2015148
2016150
2017172
2018301
2019513
2020187
2021153
2022101
202345
202472
202558
202639

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zegerid (Omeprazole/Sodium Bicarbonate)

2024 spending

$3.3M

Beneficiaries

252

667 claims

Per beneficiary

$12,949

$105.22 per unit

View as table
YearSpending
2020$8,698,746
2021$7,954,260
2022$8,461,055
2023$8,514,993
2024$3,263,247

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,390 on PubMed

Sponsor: Salix

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.